One of the pathological hallmarks of Alzheimer's disease (AD) is the presence of extracellular plaques resulting from the accumulation of beta-amyloid peptide (Aβ). To date, a definitive cure for this disease is still lacking as the currently approved drugs used are mainly symptomatic treatments. The revolutionary discovery of extracellular vesicles (EVs) has shed new light on the development of disease-modifying treatments for AD, owing to their potential in delivering the therapeutic agents to the brain. The feasibility of harnessing EVs for clinical applications is highly dependent on the donor cell, which determines the intrinsic properties of EVs. The merit of mesenchymal stem cells (MSCs) as therapeutic delivery vehicles, and the proven therapeutic effects of the EVs derived from these cells, make researchers esteem MSCs as ideal producers of EVs. Therefore, MSC-derived EVs (MSC-EVs) emerge to be an appealing therapeutic delivery approach for the treatment of AD. Here, we discuss perspectives on the therapeutic strategies using MSC-EVs to treat AD and the associated challenges in clinical application.
Introduction
The remarkable progress in understanding the molecular mechanisms of human diseases has generated new excitement in biomedical research, which in turn had led to the discovery of potential therapeutic approaches. In the past several decades, the development of stem cell therapy and its continuous advancement has gained immense attention. Among all stem cell types, mesenchymal stem cells (MSCs), which have been intensively studied, hold great promise in disease treatments, particularly in the fields of regenerative medicine and therapeutic gene delivery. The therapeutic efficiency of MSCs was initially attributed to their migration and engraftment to the target site. However, studies on the bio-distribution of MSCs after systemic infusion have indicated that the localization of MSCs at target tissues is rare (1) (2) (3) , likely reflecting the fact that the therapeutic effects of these cells are not predominantly imputed to their presence at the target site and could be related to the factors secreted by the cells.
Recently, accumulating evidence has shown that extracellular vesicles (EVs) that are secreted from cells play a vital role in cell-to-cell communication (4) . MSC-derived EVs (MSC-EVs) were reported to exert therapeutic effects similar to those of their whole-MSC counterparts, thereby indicating a role of EVs as key mediators of the therapeutic efficacy of MSCs (5, 6) . These nano-sized (50-150 nm in diameter) vesicles, with the potential to transport a wide range of biomolecules over a long distance between cells (7), coupled with their ability to cross biological barriers (8), have ignited the light of hope in treating intractable neurodegenerative diseases such as Alzheimer's disease (AD). In this review, we outline the current knowledge in the role of EVs in AD treatment. We also discuss the therapeutic perspective of utilizing MSC-EVs in treating AD as well as the possible challenges of using EVs as a novel cell-free therapy.
MSCs and their characteristics
Slightly more than half a century ago, scientists discovered multipotent bone marrow cells. Since then, these cells have been given many different names (9-11) but the term 'mesenchymal stem cells', which was first coined by Arnold Caplan in 1991 (12) , has remained popular in current everyday use. Such MSCs can be isolated from various tissues and organs, such as peripheral blood (13) , umbilical cord blood (14) , adipose tissue (15) , amniotic fluid (16), placenta (17) and so forth (18) (19) (20) (21) ; yet, bone marrow remains the most abundant source of MSCs (22) .
The multipotency of MSCs confers them great capacity to undergo both self-renewal and multilineage differentiation. Studies have shown that MSCs are able to differentiate into adipocytes, osteoblasts, chondrocytes (23) , muscle cells (24) (25) (26) , endothelial cells (27) , neurons (28) , keratocytes (29) , hepatocytes (30, 31) and pancreatic β-cells (32) . In addition to their multilineage differentiation potential, MSCs also exhibit immunoprivileged properties (33) . MSCs are thought to be non-immunogenic or hypo-immunogenic because they do not express MHC class II and co-stimulatory molecules (CD80, CD86 or CD40) (34) . In addition, the ability of MSCs to suppress T lymphocyte activation and proliferation (35, 36) , to impair dendritic cell differentiation and maturation (37, 38) as well as to inhibit B cell proliferation (39) also contributes to their immunosuppressive effect.
Homing and migration are other distinctive features of MSCs. Numerous studies have demonstrated the homing potential of MSCs to the site of injury while also exerting their therapeutic effects on the damaged tissues at the same time (40) (41) (42) . This homing ability is restricted not only to the site of injury, but also toward tumor environments (43) . Although the underlying homing mechanisms remain unclear, it has been postulated to be similar to the concept of leukocyte migration during inflammation (44) .
The therapeutic potential of MSCs
Over the past few decades, tissue regeneration and therapeutic gene delivery have received much research and clinical interest. These new generations of cellular therapy hold the promise of treating a wide range of diseases including both genetic and acquired diseases, leading to an improved quality of life.
MSCs, with their distinctive properties of differentiation potential as well as the homing and migration abilities, are ideal candidates for use in regenerative medicine (45, 46) . The emerging evidence on the immunomodulatory properties of MSCs has made them even more attractive for use in tissue and organ repair as the rejection of transplanted cells in recipients has always been an issue in transplantation (47) . For instance, there is growing enthusiasm among researchers to evaluate MSCs as an alternative approach for treating myocardial infarction (MI) and osteogenesis imperfecta (OI) owing to their myogenic and osteogenic differentiation potential, respectively (34, 48, 49) . The therapeutic potential of MSCs in the repair of other tissues has also been demonstrated in multiple independent studies. Currently, extensive research and clinical trials are underway to exploit MSCs as a tool to treat diseases including type-1 diabetes (50), neurological diseases (51) and kidney disease (52) .
On top of that, MSCs are also highly favored in gene therapy, a powerful therapeutic approach that may offer a cure for severe diseases refractory to conventional treatment (53) . Cancer is the most extensively evaluated disorder for gene therapy applications. The standard treatments for cancer such as surgery, radiotherapy and chemotherapy, are often highly invasive and less effective as a result of cancer recurrence and metastasis. MSCs can be readily transduced with most of vectors and can efficiently express and secrete the therapeutic agents, thus contributing to their versatility as the most promising cellular vehicles in gene delivery (54) (55) (56) . Moreover, the tumor-homing ability of MSCs, which allows them to specifically deliver anti-cancer agents to the target sites, is likely to make the cells more effective in treating both isolated tumors and metastatic diseases (57) . Several research groups have reported that genetically engineered MSCs show significant anti-cancer effects in various animal tumor models (58) (59) (60) .
Despite the promising results in animal models that have opened up the path of novel therapeutic strategies for cancers with the use of genetically engineered MSCs, concerns have been raised against these cells for their recently reported tumorigenic roles. There are conflicting reports in terms of the effect of MSCs in tumor progression. Several studies showed that MSCs exert inhibitory effects on tumor progression by increasing inflammatory infiltration, inhibiting angiogenesis and suppressing cellular signaling. However, there is also plentiful evidence supporting the role of MSCs in promoting tumor growth. For example, MSCs have been shown to migrate to the tumor site and integrate into tumorassociated stroma. Cancer cell-derived cytokines have also been shown to induce MSCs to secrete soluble factors, which then promote tumor growth in a paracrine manner (61) (62) (63) (64) . In addition, differentiation of MSCs into endothelial cells and pericytes also contributed to tumor angiogenesis (65) . This cross-talk between cancer, MSCs and other neighboring cells is believed to create a tumor niche that enables tumor progression, invasion and metastasis. To date, the reason for the contradictory role of MSCs in tumor growth remains unknown.
In spite of the presence of ambiguity of the exact role of MSCs, a decent amount of research that delves into its beneficial role is still going on. It was initially thought that the physically close proximity of transplanted MSCs and their subsequent differentiation or gene expression contributed to the substantial therapeutic effects mentioned above. However, it has recently been suggested that the mechanism underlying the therapeutic efficacy of MSCs could be executed by paracrine effects. This hypothesis stemmed from the findings of studies that suggest secreted factors in MSCderived conditioned medium, rather than cell incorporation, could be accountable for the significant therapeutic impact, in both in vitro and in vivo settings (66) (67) (68) .
In addition to these studies, Gnecchi et al. (69) have successfully demonstrated that the intramyocardial injection of conditioned medium from Akt-overexpressing MSCs reduces the infarct size in an acute MI (AMI)-rodent model and, more importantly, this effect is found to be similar as that seen in the animals injected with the parental cells. Furthermore, the observation of transplanted MSCs being trapped in a wide variety of organs, instead of the target side, also supports the notion that the therapeutic efficacy of MSCs is not solely dependent on cell engraftment (70) . MSCs were also reported to secrete large amount of EVs, leading to considerable attention being paid to investigate the possible role of this lipid membrane vesicle as an active therapeutic factor secreted by MSCs.
Extracellular vesicles
EVs were described in the 1980s by Pan and Johnstone (71) . These vesicles can be categorized into different subtypes, mainly based on their origin of biogenesis. Presently, exosomes are the most well characterized and widely studied EVs. In general, they are defined as nano-sized vesicles ranging from 50 to 150 nm in diameter and have a floating density of 1.10-1.18 g ml −1 on a sucrose density gradient. Exosomes are generated from the inward budding of late endocytic compartments, named as multivesicular bodies (MVBs), and are subsequently released to the extracellular milieu as membranous vesicles upon fusion with the plasma membrane. This endows them with a plasma membrane similar to that of their parental cells and enriches them with lipid rafts of cholesterol, sphingomyelin and ceramide (72) (73) (74) . Despite being classified according to their biogenesis, the precise terminology for membranous vesicles is often ambiguous and the terms 'extracellular vesicles', 'exosomes', 'microvesicles', 'shedding vesicles', etc. are used interchangeably (75) . To avoid confusion, throughout this review we will use the term 'extracellular vesicles' to represent all secreted vesicles in the extracellular space.
After many years of intense research, EVs are no longer being viewed as disposal vehicles with the sole function of eliminating unwanted proteins and biomolecules. They are increasingly recognized as important messengers in facilitating intercellular communication. It has been known that nearly all cell types are capable of secreting EVs. Owing to their stable lipid bilayer membrane structure and the ability to traffick in biological fluids, EVs are capable of transporting and transferring bioactive molecules (proteins and RNAs) between cells (7). Through this exchange of proteins and genetic materials, they have been reported not only to function in normal physiological processes (76, 77) , but also to be associated with the pathogenesis of various diseases and cancers (78) (79) (80) .
EVs are also found to play an essential role in cell-cell communication in the central nervous system (CNS) (81) . Taken together with their ability to cross the blood-brain barrier (BBB) (8), these vesicles have come into the limelight as a potential therapeutic tool for the treatment of neurodegenerative diseases such as AD.
Association of EVs with AD

Pathogenic/detrimental role of EVs in AD
AD is the most common type of dementia, accounting for up to 75% of all cases. It is a progressive neurodegenerative disease characterized by the overproduction and/or impaired clearance of beta-amyloid peptide (Aβ) in the brain. The deposition of Aβ has been suggested to be the causative factor for the destruction and death of neurons, leading to the gradual erosion of memory and subtle decline in cognitive ability (82) (83) (84) .
EV production in the brain has been suggested to contribute to the pathogenesis and progression of AD.
The association between EVs and AD was first raised from the finding that showed the increment and accumulation of Aβ in MVBs within the nerve terminals of AD transgenic mice and the human brain (85) . It was then further described by Rajendran et al. (86) that the intracellularly accumulated Aβ in MVBs is routed to the extracellular environment via EVs as a result of fusion with the plasma membrane. In addition, they observed that neutritic plaques in the hippocampal section of AD patients are enriched with EV marker, Alix. This phenomenon was not observed in the hippocampus of a normal control brain, indicating the correlation between the secretion of Aβ and EVs (86) .
Since then, research interest on EVs in the pathogenesis of AD has increased, with the aim of identifying the role of EVs in the metabolism of Aβ as well as the effect of Aβ-associated EVs on neuronal functions through their interaction with the resident cells in the brain. The aggregation of Aβ has been shown to be dependent on EV secretion. The inhibition of neutral sphingomyelinase 2 (nSMase2), which regulates EV biosynthesis, prevents the secretion of ceramide and EVs, thus leading to the reduction of amyloid plaque formation in the brains of an AD mouse model (87) . In contrast, ceramidetreated mice, compared with the controls, show increased levels of serum EVs and enhanced amyloid plaque formation (88) , suggesting that EVs are associated with the metabolism of Aβ in AD.
Non-neuronal cell-derived EVs have also been reported to exert a pathogenic role in AD. EVs secreted from microglia were shown to promote the formation of neurotoxic Aβ and act as a potent driver in damaging neuronal cells (89) . This is, however, contradictory to the previously reported physiological function of microglia in controlling extracellular Aβ aggregation via phagocytosis and degradation. The authors suggested that the secretion of neurotoxic Aβ-carrying EVs from microglia might occur when the intracellular pathway of Aβ degradation becomes saturated. Therefore, the release of EVs to their extracellular environment is the only way for microglia to eliminate un-degraded Aβ. Although the precise mechanism is yet to be defined, previous studies have reported the re-secretion of phagocytosed Aβ from microglia (90) .
Aβ is well known for its toxicity to neurons, but little is known about its effect on non-neuronal cells, such as astrocytes, which play a supportive role for neurons in the CNS. The dysfunction or death of astrocytes might have implications in neurons and their functions, consequently contributing to neurodegeneration in AD. A study done by Wang et al. has shown that treatment of Aβ triggers the secretion of EVs enriched with ceramide and prostate apoptosis response 4 (PAR4) from astrocytes via an nSMase2-dependent pathway, which exerts a pro-apoptotic effect on astrocytes in the mice (91) .
Tau, another AD-related protein, was also reported to be associated with EV secretion. In the study, Asai et al. (92) speculated that microglia phagocytosed Tau aggregates and facilitated the transfer of EV-bounded Tau to neurons via exocytosis. The authors emphasized the importance of microglia and nSMase2 activity in the propagation of Tau protein and neurotoxicity in the brain. Depletion of microglia in two different tauopathy mouse models via intracerebroventricular
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infusion of clodronate liposome or PLX3397 treatment, as well as inhibition of EV synthesis through silencing of nSMase2 expression or inhibiting nSMase activity showed remarkable reduction of Tau contents in EVs as compared with the control group.
Neuroprotective role of EVs in AD
There are two sides to every coin-although the role of EVs in the pathogenesis of AD has been proposed, accumulating evidence shows that EVs might also play a beneficial role in the clearance of Aβ in the AD brain. Yuyama et al. (93) have conducted an elegant study on the neuroprotective functions of EVs, highlighting a novel mechanism of Aβ clearance by microglia in association with neuronal EVs. They demonstrated that (i) sphingolipid-metabolizing enzyme is essential for the secretion of EVs from neurons; (ii) these extracellular neuronal-EVs further promote Aβ amyloidgenesis through glycosphingolipids (GSLs) on their surface; and (iii) EV-Aβ fibril complexes are subsequently internalized by microglia and transported to lysosomes for degradation (93) .
The suggested machinery was further validated in their subsequent in vivo study (94) . Indeed, in AD transgenic mice, intracerebrally injected neuroblastoma-derived EVs were shown to bind to Aβ and subsequently be incorporated into microglia. Interestingly, the continuous injection of exogenous EVs shows a marked reduction of Aβ deposition and Aβ-associated synaptotoxicity in the animals. This finding suggests the rapid clearance of EV-bounded Aβ by microglia before the formation of Aβ deposits (94) . Nevertheless, the authors also acknowledged the importance of normal phagocytic activity of microglia in this EV-mediated Aβ clearance. Without the normal function of microglia, the free EV-bounded Aβ protein could resume a pathological role in plaque formation or even the onwards dissemination of the protein.
In addition to the EV-mediated Aβ clearance by microglia, the biomolecules contained in naive EVs might also contribute to their protective effect in AD. In a previous study, we have observed that EVs secreted from human adipose tissue derived-MSCs (ADSCs) are enriched with neprilysin (NEP), an Aβ-degrading enzyme in the brain. Co-culture of ADSCs with a genetically modified neuroblastoma cell line that overproduced human Aβ (N2a cells) shows a significant decrease of both extracellular Aβ and intracellular Aβ in N2a cells. We suggest that NEP-enriched EVs are released from ADSCs and incorporated into N2a cells, thus leading to the decreased level of intracellular Aβ observed in the recipient cells (95) .
The neuroprotective effect of NEP in the stem cell secretome is further supported by a study done by Ahmed et al., in which functional NEP was detected in the dental pulp stem cell (DPSC) secretome and was shown to degrade Aβ 1-42 and reduced Aβ-induced toxicity on neuroblastoma cells (SH-SY5Y) in vitro. The expression of NEP in DPSCs was reported to be higher than in both BMSCs and ADSCs (96) . Although concrete evidence for either the pathogenic or seemingly favourable aspects of EVs in AD remains elusive, recent findings have nonetheless helped to improve the current understanding of the mechanisms of AD onset and facilitate the subsequent development of potential therapeutic approaches.
Therapeutic perspectives of MSC-EVs in the treatment of AD
Most of the drugs currently available for the treatment of AD in the market merely alleviate the manifestation of the disease and slow down its progression. These drugs are by no means able to reverse or cure the disease. Therefore, there is a pressing need to develop a disease-modifying treatment that could directly tackle the pathogenic process of the disease, with the hope not only to completely stop the disease progression, but also to restore the function of the damaged brain. In this context, EVs could be exploited as useful natural vehicles for therapeutic delivery of a wide variety of potential disease-modifying molecules, owing to their possible ability to cross the BBB for horizontal transferring of biologically active molecules between cells (97) .
From the clinical and manufacturing point of view, we propose the use of MSCs as the cellular source in producing EVs for therapeutic application in AD treatment. The availability of MSCs in a wide range of tissues and the ease of their isolation, as well as their large capacity in in vitro propagation (98) have made these cells highly desirable as potential producers of EVs (Fig. 1) . Such EVs, on top of sharing a conserved set of proteins, are also known to acquire donor-derived properties (99, 100) . Proteomic analysis of MSC-EVs has shown consistent immune tolerance properties similar to those of MSCs (101, 102) , further adding their value as allogenic and autologous natural delivery vehicles. In addition, MSCs are the preferred producers of EVs, owing to the amenability of these cells to gene modification, thereby conferring them the ability to produce EVs that are enriched with desired therapeutic factors (103, 104) .
Most importantly, MSC-EVs have shown encouraging therapeutic effects in a wide spectrum of tissue injuries, such as those in the liver, lungs, kidneys, heart and brain [Reviewed in refs. 105, 106] . The first report describing the potential therapeutic use of MSC-EVs was in an acute kidney injury (AKI) mouse model. The EVs derived from MSCs have been demonstrated to induce the proliferation of tubular cells, thereby promoting renal functional and morphologic recovery in the mice (6) . Moreover, in brain injuries, systemic administration of MSC-EVs has been reported to significantly improve the neurologic outcome in a rat model of stroke (107) . The MSC-EVs were shown to induce neurite outgrowth, an effect believed to be mediated through the transfer of miR-133b from MSCs to neurons via secreted EVs in both in vitro and in vivo settings (104, 108) . Altogether, the evidence suggests an optimistic outlook for utilizing MSC-EVs as a cell-free therapy in treating AD.
To further pursue the development of MSC-EVs as a therapeutic delivery vehicle to treat AD, MSCs can be genetically modified to enhance the therapeutic effect of EVs, by employing the reduction of the Aβ level as the core strategy (Fig. 2) . There are two ways to decrease Aβ levels in the brain: (i) termination of Aβ peptide production; and (ii) promotion of the clearance of accumulated Aβ peptides, for example by increasing degradation of Aβ peptides. Neurotoxic Aβ peptides are derived from the cleavage of Aβ precursor protein (APP) by β-and γ-secretases (109-111). These enzymes are therefore attractive targets that can effectively block the production of Aβ through inhibition of their proteolytic activities. In this context, MSCs can be genetically modified to secrete EVs enriched with therapeutic factors, such as small interfering RNA (siRNAs) that target β-and γ-secretase enzymes.
This principle of EV-mediated siRNA delivery to the brain has recently been confirmed by Alvarez-Erviti et al. (97) The authors showed that the delivery of β-site APP-cleaving enzyme 1 (BACE-1) siRNA, which targets β-secretase, resulted in 60% of BACE-1 gene knockdown, thus leading to a 55% reduction of Aβ level in the animals (97) . Based on this proof of concept study, siRNA targeting of γ-secretase could also be encapsulated into MSCs and delivered to the brain region via MSC-EVs. Indeed, γ-secretase inhibitors have been put forward for consideration as a treatment for AD since their effects in reducing Aβ production have been demonstrated in APP-overexpressing transgenic mice (112) .
However, γ-secretase is also reported to be involved in other signaling pathways such as Notch signaling, which is essential for cell development and differentiation, thereby raising concerns about potential side-effects that may result from the affected Notch signaling (113) . Thus, before γ-secretase can be successfully utilized as a therapeutic target, the differential mechanism of γ-secretase function in APP cleavage and the Notch signaling pathway must be clearly elucidated in order to develop γ-secretase inhibitors that specifically affect APP and that simultaneously spare the Notch signaling (114) . On the other hand, transfer of Aβ-degrading enzymes via EVs to the brain may also possibly improve the clearance of Aβ and therefore impede the progress of AD. For instance, the Aβ-degrading enzymes, insulin-degrading enzyme (IDE) and NEP, which have been shown to reduce Aβ levels (115), could be selectively enriched in EVs through overexpression in the parental MSCs.
Apart from that, to maximize the therapeutic outcome of MSC-EVs, enhancing delivery specificity and minimizing undesirable off-target effects are also essential points to be pondered upon. These goals may be achieved through the modification of the EV membrane, thereby augmenting the docking of EVs to neuron-specific receptors or ligands. Successful delivery to the brain has been demonstrated by targeting the acetylcholine receptor through fusion of EV membrane protein, Lamp2b, with the neuron-specific RVG peptide (97) .
Instead of docking to neurons, specific delivery of EVs can also be achieved through targeting non-neuronal resident cells in the brain. For example, the fusion of EV membrane proteins to peptides that recognize the gap junction protein, connexin 43, which is highly expressed in astrocytes (116) , might enhance the tropism of EVs toward the brain (117, 118) . In essence, it is worthy to delve into the search for other new cell-specific ligand targets that can precisely guide EV migration toward the desired destination. Nonetheless, determining the optimal administration method of EVs, one of the success-limiting steps, is crucial to maximize the efficacy of EV-mediated treatment. For example, intra-nasal administration has been shown to rapidly deliver EVs to the brain, and the repeated administration of these vesicles continued to exerts a therapeutic effect without causing any toxicity or behavioral abnormalities in the mice (8).
Challenges in the clinical application of MSC-EVs
Large-scale production of clinically compliant MSCs for the generation of EVs is by all means necessary in translating MSC-derived EVs into therapeutic reality. The feasibility of large-scale production has been demonstrated by Chen et al. (119) on the basis of their work that successfully immortalised human embryonic stem cell-derived MSCs (hESC-MSCs) by overexpressing the MYC gene through lentivirus transduction. Although this appears to be an infinite source for EV production, the slight phenotypic changes in the transformed cells observed in the study, as well as other safety issues that are likely to arise from any unidentified effects of MYC overexpression, should not be overlooked. Therefore, other potential methods to enhance the production of EVs from MSCs, such as the overexpression of nSMase2 and Rab family members (Rab27a, Rab27b and Rab35) may be further explored.
Moreover, the precise content of MSC-EVs remains largely unknown because these vesicles contain many molecules that are yet to be identified. This may lead to the possible concurrent transport of these unidentified endogenous biomolecules together with the exogenous therapeutic agent to the recipient cells via MSC-EVs, thus causing unwanted side effects. Therefore, a more in-depth and rigorous characterization of the contents of these vesicles is needed to ensure their safety. Last, but not least, prior to clinical application, it is also crucial to examine the optimal dosage of MSC-EVs and the effect of their repeated administration to achieve the best therapeutic efficiency while minimizing undesired toxicity and other adverse effects.
Conclusions
Thus, the development of genetically modified MSC-EVs might open a new horizon for therapeutic strategies in AD and other neurodegenerative diseases. The MSC-EVs are superior to cell-based therapy in terms of safety as there is no involvement of cells that could potentially elicit unknown side-effects. However, its seemingly promising therapeutic potential should not overshadow the unaddressed issues, particularly because research in this field is still in its infancy. Hence, additional studies are needed to meet these challenges in order to improve the therapeutic intervention for AD treatment. 
